{"entity":{"id":"nct06464055","kind":"trial","name":"A Study of GQ1010 in Subjects With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Dose Escalation in advanced solid tumours, run by GeneQuantum Healthcare (Suzhou) Co., Ltd., now recruiting.","summary":"A Study of GQ1010 in Subjects With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06464055 by GeneQuantum Healthcare (Suzhou) Co., Ltd., with 260 participants planned, started 2024-05-23 and due to reach its primary completion in 2028-05-23. Interventions recorded: Dose Escalation, Dose Expansion1, Dose Expansion2, Dose Expansion3 and phase II.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06464055","url":"https://clinicaltrials.gov/study/NCT06464055"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06464055","phase":"1/2","setting":"A Phase I/II, Multicenter, Open-Label, Dose-Escalation and Extension Study of GQ1010(an Anti-Trop2 ADC) in Subjects With Advanced Solid Tumors","sponsor":"GeneQuantum Healthcare (Suzhou) Co., Ltd.","enrolled":260,"outcomes":[]},"route":"/trials/nct06464055/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}